[ALKS] Alkermes plc

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 57.99 Change: 1.68 (2.98%)
Ext. hours: Change: 0 (0%)

chart ALKS

Refresh chart

Strongest Trends Summary For ALKS

ALKS is in the long-term down -37% in 1 year and up 160% in 15 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension a

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-1.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.08% Sales Growth - Q/Q-7.96% P/E-43.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-1.89% ROE-2.56% ROI-2.04%
Current Ratio8.79 Quick Ratio8.36 Long Term Debt/Equity0.39 Debt Ratio0.08
Gross Margin72.77% Operating Margin-15.17% Net Profit Margin-5.6% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.94 M Cash From Investing Activities-31.78 M Cash From Operating Activities-13.33 M Gross Profit120.95 M
Net Profit-46.11 M Operating Profit-52.52 M Total Assets1.91 B Total Current Assets1.02 B
Total Current Liabilities134.22 M Total Debt354.81 M Total Liabilities515.68 M Total Revenue151.37 M
Technical Data
High 52 week67.26 Low 52 week33 Last close34.34 Last change-0.03%
RSI34.49 Average true range1.63 Beta1.3 Volume502.8 K
Simple moving average 20 days-7.13% Simple moving average 50 days-13.72% Simple moving average 200 days-25.44%
Performance Data
Performance Week0.73% Performance Month-14.21% Performance Quart-23.43% Performance Half-24.97%
Performance Year-31.53% Performance Year-to-date-37.26% Volatility daily3.16% Volatility weekly7.06%
Volatility monthly14.47% Volatility yearly50.11% Relative Volume195.73% Average Volume806.49 K
New High New Low

News

2019-03-22 18:39:48 | Top Insider Buys Highlight

2019-03-21 09:54:01 | Alkermes Focuses on Pipeline, Depends on Partners for Funds

2019-03-20 09:00:00 | Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development

2019-03-16 09:30:01 | Why Is Alkermes ALKS Up 4.7% Since Last Earnings Report?

2019-03-13 15:42:06 | Alkermes plc’s NASDAQ:ALKS Path To Profitability

2019-03-07 08:48:01 | Allergan's Depression Candidate Fails in Studies, Stock Down

2019-03-06 09:24:00 | REVIEWAPALOOZA!: 5-Stock Samplers

2019-03-05 16:01:00 | Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference

2019-02-28 07:25:00 | Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-02-27 16:25:09 | Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates

2019-02-26 08:32:01 | Alkermes' ALKS and Biogen's NDA for BIIB098 Accepted by FDA

2019-02-26 07:00:00 | Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors

2019-02-25 17:54:19 | CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-25 15:49:00 | FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Alkermes plc, Inc. ALKS and Lead Plaintiff Deadline- February 25, 2019

2019-02-25 14:30:08 | CLASS ACTION UPDATE for YRIV, ALKS, MKL and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-25 12:48:00 | FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. ALKS and Lead Plaintiff Deadline- February 25, 2019

2019-02-25 11:29:47 | CLASS ACTION UPDATE for DBVT, ALKS, GSM and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-25 10:43:00 | DEADLINE ALERT - IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC

2019-02-25 07:30:00 | Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

2019-02-24 14:48:00 | DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. ALKS and Lead Plaintiff Deadline- February 25, 2019

2019-02-24 14:21:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline - ALKS

2019-02-24 14:00:00 | CLASS ACTION UPDATE for DNKEY, ALKS, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-24 11:40:00 | IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC Class Action Update

2019-02-24 10:57:00 | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALKS, GSM, UXIN and AVP

2019-02-22 17:25:00 | CLASS ACTION UPDATE for ALKS, MU, SVXY and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-22 15:00:00 | DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. ALKS and Lead Plaintiff Deadline - February 25, 2019

2019-02-22 14:07:09 | Alkermes Public Limited Company Reminder: Pawar Law Reminds of Important February 25, 2019 Lead Plaintiff Deadline in Class Action – ALKS

2019-02-22 14:01:35 | CLASS ACTION UPDATE for DBVT, AXGN, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-22 13:05:04 | Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. ALKS

2019-02-22 12:47:15 | DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-02-22 11:13:11 | CLASS ACTION UPDATE for IMMU, ALKS, UXIN and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-22 10:00:00 | Immunomedics, Inc. IMMU, Alkermes plc, Inc. ALKS & DXC Technology Company DXC - Bronstein, Gewirtz & Grossman, LLC Class Action Update

2019-02-22 07:30:00 | CLASS ACTION UPDATE for PRGO, DBVT, ALKS and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-21 17:45:00 | CLASS ACTION UPDATE for AXGN, ALKS, GE and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-21 17:16:43 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline  – ALKS

2019-02-21 16:57:56 | Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc ALKS

2019-02-21 15:58:00 | DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. ALKS and Lead Plaintiff Deadline: February 25, 2019

2019-02-21 11:53:07 | CLASS ACTION UPDATE for IMMU, DBVT, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-21 10:47:00 | Immunomedics, Inc. IMMU, Alkermes plc, Inc. ALKS & DXC Technology Company DXC Bronstein, Gewirtz & Grossman, LLC Class Action Update

2019-02-21 09:44:02 | The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis

2019-02-20 19:45:00 | CLASS ACTION UPDATE for ALKS, GSM, ASTE and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-20 16:30:00 | 6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

2019-02-20 16:11:42 | ALKS UPCOMING FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important Deadline in Securities Class Action – ALKS

2019-02-20 16:01:00 | Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-20 15:45:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline – ALKS

2019-02-20 14:09:07 | CLASS ACTION UPDATE for YOGA, ARLO, ALKS and GSM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-02-20 13:05:00 | SINGLE TICKER NOTICE: Pawar Law Group Reminds of February 25 Deadline in Securities Class Action Lawsuit Against Alkermes Public Limited Company – ALKS

2019-02-20 12:56:00 | DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. ALKS and Lead Plaintiff Deadline - February 25, 2019

2019-02-20 12:17:56 | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AXGN, ALKS, MU and TAP

2019-02-20 10:44:00 | Immunomedics, Inc. IMMU, Alkermes plc, Inc. ALKS and DXC Technology Company DXC Bronstein, Gewirtz & Grossman, LLC Class Action Update